, Volume 183, Issue 1, pp 1–12 | Cite as

Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h

  • Vincenzo Teneggi
  • Stephen T. Tiffany
  • Lisa Squassante
  • Stefano Milleri
  • Luigi Ziviani
  • Alan Bye
Original Investigation



Sustained-release (SR) bupropion enhances quit rates of smokers, generally decreases tobacco withdrawal, and in some studies, reduces craving.


Investigate the effects of SR bupropion on craving and withdrawal during cigarette abstinence.


Twenty three smokers participated in three 17-day periods composed of 14 out-patient days followed by 3 (72 h) in-patient days. During the out-patient days, subjects received SR bupropion, placebo, or no drug. During the in-patient days, subjects were abstinent from cigarettes on two occasions while receiving either SR bupropion or placebo and smoked freely during the other occasion. SR bupropion was titrated over the first three out-patient days followed by a fixed dose (300 mg/day) for 14 days (including the three in-patient abstinence days). Cigarette craving, withdrawal, and selected physiological measures were assessed repeatedly over the 72-h periods.


During the 72-h periods, craving intensity was significantly lower with free smoke and SR bupropion than with placebo, and significantly lower during free smoke than during SR bupropion. Overall withdrawal symptoms were significantly lower with free smoke than with either placebo or SR bupropion. Among individual withdrawal symptoms (excluding craving), appetite increase was significantly reduced during SR bupropion compared to placebo. During placebo and SR bupropion, craving intensity displayed a circadian pattern that was different from that observed during free smoke.


SR bupropion reduced craving and appetite increase during smoking abstinence. These findings support the hypothesis that craving and withdrawal symptoms may be controlled by distinct central nervous system pathways.


SR bupropion Smoking Craving Withdrawal 



The research was funded by GlaxoSmithKline, Italy.


  1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi S, Mayo MS (2002) Sustained release bupropion for smoking cessation in African Americans. A randomise controlled trial. JAMA 288(4):467–474CrossRefGoogle Scholar
  2. American Psychiatry Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatry Association, Washington, DC, p 244Google Scholar
  3. Balfour DJK (1994) Neuronal mechanisms underlying nicotine dependence. Addiction 89:1419–1423PubMedCrossRefGoogle Scholar
  4. Benowitz NL (1993) Nicotine replacement therapy: what has been accomplished—can we do better? Drugs 45:157–170PubMedCrossRefGoogle Scholar
  5. Brandon TH, Tiffany ST, Obremski KM, Baker TB (1990) Post-cessation cigarette use: the process of relapse. Addict Behav 15:105–114CrossRefPubMedGoogle Scholar
  6. Breslau N, Kilbey MM, Andreski P (1992) Nicotine withdrawal symptoms and psychiatric disorders: finding from epidemiologic studies. Am J Psychiatry 149:464–469PubMedGoogle Scholar
  7. Cohen J (1988) Statistical power analyses for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ, pp 25–26Google Scholar
  8. Cohen J (1992) A power primer. Psychol Bulletin 112(1):155–159CrossRefGoogle Scholar
  9. Cohen J, Cohen P (1975) Applied multiple regression/correlation analyses for the behavioral sciences. Lawence Erlbaum, Hillsdale, NJGoogle Scholar
  10. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11(2):133–141PubMedGoogle Scholar
  11. Corrigal WA, Franklin KB, Coen KM, Clark PBS (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285–289PubMedCrossRefGoogle Scholar
  12. Cox LS, Tiffany ST, Christen AG (2001) Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical settings. Nicotine Tob Res 3:7–16CrossRefPubMedGoogle Scholar
  13. Curry SJ, Mc Bride CM (1994) Relapse prevention for smoking cessation. Review and evaluation of concepts and interventions. Annu Rev Public Health 15:345–366CrossRefPubMedGoogle Scholar
  14. Dalsgrað OJ, Hansen NC, Søes-Petersen U, Evald T, Høegholm A, Barber J, Vestbo J (2004) A multicenter, randomised, double-blind, placebo controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 6(1):55–61CrossRefPubMedGoogle Scholar
  15. Davies GM, Willner P, Morgan MJ (2000) Smoking related cues elicit craving in tobacco chippers: a replication and validation of the two-factor structure of the Questionnaire of Smoking Urge. Psychopharmacology 152(3):334–342CrossRefPubMedGoogle Scholar
  16. Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314CrossRefPubMedGoogle Scholar
  17. Di Chiara G, Imperato A (1988) Drug abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274–5278PubMedCrossRefGoogle Scholar
  18. Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 155:52–57CrossRefPubMedGoogle Scholar
  19. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DPL (2002) The effect of bupropion sustained release on cigarette craving after smoking cessation. Clin Ther 24(4):540–551CrossRefPubMedGoogle Scholar
  20. Fagerström KO (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualisation of treatment. Addict Behav 3:235–241CrossRefPubMedGoogle Scholar
  21. Ferris RM, Cooper BR (1993) Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monogr 11:2–14Google Scholar
  22. Ferry LH (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26:653–669PubMedGoogle Scholar
  23. Fiore MC, Smith SS, Jorenby DE, Baker TB (1994) The effectiveness of the nicotine patches for smoking cessation: a meta-analysis. JAMA 271:1940–1947CrossRefPubMedGoogle Scholar
  24. Fiore MC, Bailey WC, Cohen SJ et al (2000) Treating tobacco use and dependence. Clinical practice guideline. US Department of Health and Human Services Public Health Service, Rockville, MDGoogle Scholar
  25. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52:53–61CrossRefPubMedGoogle Scholar
  26. Glassman AH (1993) Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150:546–553PubMedGoogle Scholar
  27. Gorin SS, Heck JE (2004) Meta-analysis of the efficacy of tobacco counselling by health care providers. Cancer Epidemiol Biomarkers Prev 13(12):2012–2022PubMedGoogle Scholar
  28. Gritz ER, Carr CR, Marcus AC (1991) The tobacco withdrawal syndrome in unaided quitters. Br J Addict 86:57–69PubMedCrossRefGoogle Scholar
  29. Halaris A, Zhu H, Feng Y, Piletz JE (1999) Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci 881:445–451PubMedCrossRefGoogle Scholar
  30. Henningfield JE, Schuh LM, Jarvik ME (1995) Pathophysiology of tobacco dependence. Psychopharmacology: the fourth generation of progress. Raven, New YorkGoogle Scholar
  31. Hilleman DE, Mohiuddin SM, Del Core MC, Sketch H (1992) Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 152:350–352CrossRefPubMedGoogle Scholar
  32. Horst WD, Preskorn SH (1998) Mechanism of action and clinical characteristics of three atypical antidepressant: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254CrossRefPubMedGoogle Scholar
  33. Hughes JR (2000) New treatments in smoking cessation. CA Cancer J Clin 50:143–151PubMedCrossRefGoogle Scholar
  34. Hughes JR, Glasela M (1993) Transdermal nicotine for smoking cessation. Health Values 17:25–31Google Scholar
  35. Hughes JR, Hatsukami DK (1992) The nicotine withdrawal syndrome: a brief review and update. Int J Smok Cessation 1:21–26Google Scholar
  36. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984) Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83(1):82–87CrossRefPubMedGoogle Scholar
  37. Hughes JR, Stevens WG, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal. Arch Gen Psychiatry 48:52–59PubMedGoogle Scholar
  38. Hughes JR, Higgins ST, Bickel WK (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89:1461–1470PubMedCrossRefGoogle Scholar
  39. Hurt RD, Sachs DPL, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained release bupropion and placebo for smoking cessation. New Engl J Med 337:1195–1202CrossRefPubMedGoogle Scholar
  40. Jamerson BD, Nides M, Jorenby DE, Danahue R, Garret P, Johnston JA, Fiore MC, Rennard SI, Leishow SJ (2001) Late term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy and placebo. Clin Ther 23(5):744–752CrossRefPubMedGoogle Scholar
  41. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto JL, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691CrossRefPubMedGoogle Scholar
  42. Kenford SL, Fiore CM, Jorenby DE, Smith SS, Wetter D, Baker TB (1994) Predicting smoking cessation. Who will quit with and without nicotine patches. JAMA 2718:589–594CrossRefGoogle Scholar
  43. Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse. Finding from three prospective studies. Exp Clin Psychopharmacol 5(2):137–142CrossRefPubMedGoogle Scholar
  44. Killen JD, Fortmann SP, Newman B, Varady A (1991) Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology 105:191–196PubMedCrossRefGoogle Scholar
  45. Klesges RC, Klesges LM, De Bon M, Shelton ML, Isbell TR, Klem M (1995) Effects of phenylpropanolamine on withdrawal symptoms. Psychopharmacology 119(1):85–91PubMedCrossRefGoogle Scholar
  46. Koob GF (2000) Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 909:171–185Google Scholar
  47. Koob GF (2003) Neuroadaptive mechanisms of addiction: studies on extended amygdale. Eur Neuropsychopharmacol 13:442–452CrossRefPubMedGoogle Scholar
  48. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 504:800–805CrossRefGoogle Scholar
  49. Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, Kligman E, Cook G (1997) Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 5:54–64CrossRefPubMedGoogle Scholar
  50. Meyer JH, Goudling VS, Wilson AA, Hussey D, Christensen BK, Houle S (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163:102–105CrossRefPubMedGoogle Scholar
  51. Miller NS, Gold MS (1993) A hypothesis for a common neuromechanical basis for alcohol and drug disorders. Psychiatr Clin North Am 16:105–117PubMedGoogle Scholar
  52. Miyata H, Yanagita T (2001) Neurobiological mechanisms of nicotine craving. Alcohol 24:87–93CrossRefPubMedGoogle Scholar
  53. Patten CA, Martin JE (1996a) Measuring tobacco withdrawal: a review of self-report questionnaires. J Subst Abuse 8(1):93–113CrossRefPubMedGoogle Scholar
  54. Patten CA, Martin JE (1996b) Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Ann Behav Med 18(30):190–200CrossRefGoogle Scholar
  55. Prochaska JO, Goldstain MG (1991) Process of smoking cessations: implications for clinicians. Clin Chest Med 12:727–735PubMedGoogle Scholar
  56. Schneider NG (1994) Smoker Compliant Scale (SCS), revised 1984. In: Kramer JJ et al (eds) 11th mental measurements year book. Buros Institute of Mental Measurements, Lincoln, NE, p 834Google Scholar
  57. Schneider NG, Jarvik ME (1984) Time course of smoking withdrawal symptoms as a function of nicotine replacement. Psychopharmacology 82:143–144CrossRefPubMedGoogle Scholar
  58. Schneider NG, Jarvik ME, Forsythe AB (1984) Nicotine vs placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 9:149–156CrossRefPubMedGoogle Scholar
  59. Schneider NG, Olmsted RE, Steinberg C, Sloan K, Daims RM, Brown HV (1996) Efficacy of buspirone in smoking cessation: a placebo controlled trial. Clin Pharmacol Ther 60(5):568–575CrossRefPubMedGoogle Scholar
  60. Sciamanna CN, Hoch JS, Duke GC, Fogle MN, Ford DE (2000) Comparison of five measures of motivation to quit smoking among a sample of hospitalised smokers. J Gen Intern Med 15:16–23CrossRefPubMedGoogle Scholar
  61. Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 30:35–39CrossRefGoogle Scholar
  62. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwanltney CJ, Paty JA, Gnys M, Evoniuk G, De Veaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33–40CrossRefPubMedGoogle Scholar
  63. Shiffman SR, West RJ, Gilbert DG (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 6(4):599–614CrossRefPubMedGoogle Scholar
  64. Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation (Cochrane review). In: The Cochrane library, issue 2. Update Software, OxfordGoogle Scholar
  65. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327PubMedGoogle Scholar
  66. Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacology 117:2–10PubMedCrossRefGoogle Scholar
  67. Tashkin DP, Kanner R, Bailey W, Anderson P, Nides MA, Gonzales D, Dozier G, Patel MK, Jamerson BD (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571–1575CrossRefPubMedGoogle Scholar
  68. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2002) Smokers deprived of cigarettes for 72 hours: effect of nicotine patches on craving and withdrawal. Psychopharmacology 164:177–187CrossRefPubMedGoogle Scholar
  69. The Transdermal Nicotine Study Group (1991) Transdermal nicotine for smoking cessation: six-week results from two multicenter controlled clinical trials. JAMA 266:3133–3138CrossRefGoogle Scholar
  70. Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240CrossRefPubMedGoogle Scholar
  71. Tønnesen P, Tonstad S, Hjalmason A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J (2003) A multicentre, randomised, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254:184–192CrossRefPubMedGoogle Scholar
  72. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis AP, Perruchoud AP, Silagy C, van Spiegel PI, Astbury C, Hider A, Sweet R (2003) Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomized study. Eur Heart J 24:946–955CrossRefPubMedGoogle Scholar
  73. UNDCP and WHO Informal Expert Committee on the Drug-Craving Mechanism (1992) Report, United Nations International Drug Control Program and World Health Organization Technical Report Series V:92–54439TGoogle Scholar
  74. US Department of Health and Human Services (1988) The health consequences of smoking: nicotine addiction, a report of surgeon general (DHHS publication N CDC 88-8406). US Government Printing Office, Washington, DCGoogle Scholar
  75. Watkins SS, Koob GF, Markou A (2000) Neuronal mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19–37CrossRefPubMedGoogle Scholar
  76. West R (1992) The nicotine replacement paradox in smoking cessation: how does nicotine gum really work? Br J Addict 87:165–167PubMedCrossRefGoogle Scholar
  77. West R, Hajek P, Mc Neill A (1991) Effect of buspirone on cigarette withdrawal symptoms and short term abstinence rate in a smokers clinic. Psychopharmacology 104:91–96PubMedCrossRefGoogle Scholar
  78. World Health Organization (1997) Tobacco or health. A global status report. WHO, Geneva, SwitzerlandGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Vincenzo Teneggi
    • 1
  • Stephen T. Tiffany
    • 2
  • Lisa Squassante
    • 1
  • Stefano Milleri
    • 1
  • Luigi Ziviani
    • 1
  • Alan Bye
    • 1
  1. 1.GlaxoSmithKlineVeronaItaly
  2. 2.Department of Psychiatry, School of MedicineUniversity of UtahUtahUSA

Personalised recommendations